Becton, Dickinson and Company $BDX Stock Sold by Forbes J M & Co. LLP

Key Points

• Forbes J M & Co. LLP reduced its Becton, Dickinson and Company stake by 86.5% in the third quarter, selling 31,495 shares and retaining 4,901 shares valued at approximately $877,000. Institutional investors collectively own 86.97% of BDX.
• BD reported quarterly revenue of $4.98 billion and adjusted EPS of $3.23, exceeding analyst expectations, while revenue increased 5.4% year over year. The company issued fiscal 2026 EPS guidance of $12.62–$12.72.
• BDX shares recently traded at $191.34, near their 12-month high of $195.99. Analysts’ consensus rating is “Hold”, with an average price target of $185.07, despite several firms maintaining Buy ratings.

Forbes J M & Co. LLP cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 86.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,901 shares of the medical instruments supplier's stock after selling 31,495 shares during the period. Forbes J M & Co. LLP's holdings in Becton, Dickinson and Company were worth $877,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BDX. SHP Wealth Management bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at $26,000. Maryland Capital Advisors Inc. lifted its stake in shares of Becton, Dickinson and Company by 13,900.0% in the 3rd quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 139 shares during the period. Meeder Asset Management Inc. lifted its stake in shares of Becton, Dickinson and Company by 152.2% in the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier's stock valued at $27,000 after purchasing an additional 102 shares during the period. Bayban bought a new position in shares of Becton, Dickinson and Company in the 4th quarter worth $36,000. Finally, Main Street Group LTD bought a new position in shares of Becton, Dickinson and Company in the 1st quarter worth $29,000. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $191.34 on Friday. The stock's fifty day simple moving average is $184.03 and its 200 day simple moving average is $163.70. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $52.72 billion, a PE ratio of 57.63, a PEG ratio of 12.93 and a beta of 0.21. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $195.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The firm had revenue of $4.98 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same period in the previous year, the firm earned $3.68 earnings per share. The company's revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, research analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company's payout ratio is 126.51%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the firm's stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares in the company, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 6,906 shares of company stock worth $1,265,855. 0.40% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts recently commented on BDX shares. Jefferies Financial Group reaffirmed a "buy" rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. UBS Group began coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a "buy" rating and a $190.00 target price on the stock. Stifel Nicolaus set a $195.00 target price on Becton, Dickinson and Company in a report on Friday, August 7th. Bank of America boosted their target price on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Monday, August 31st. Finally, Evercore set a $180.00 price target on Becton, Dickinson and Company in a research note on Monday, July 6th. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $185.07.

About Becton, Dickinson and Company

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD's Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.